Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay


24 Nov 2018


Poster display - Cocktail


Cytotoxic Therapy;  Translational Research

Tumour Site

Breast Cancer


Hanjing Xie


Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426


H. Xie1, J. Lövrot1, J.D. Lindh2, J. Bergh1, S. Sim3

Author affiliations

  • 1 Department Of Oncology And Pathology, Karolinska Institutet, 19137 - Stockholm/SE
  • 2 Department Of Clinical Pharmacology, Karolinska University Hospital, 14186 - Stockholm/SE
  • 3 Department Of Physiology And Pharmacology, Karolinska Instuitutet, 17177 - stockholm/SE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 311


We investigated the interaction of cytochrome P450 2C19 (CYP2C19) and CYP2D6 genotype on clinical outcome in tamoxifen treated breast cancer patients and evaluated the potential of modulation by menopausal status.


We investigated a cohort of breast cancer patients prescribed tamoxifen for 5 years that had been previously genotyped for CYP2D6 polymorphism. In the current study, we extended genetic analyses to encompass also CYP2C19 polymorphism by addressing presence of the defective CYP2C19*2 and the ultra-rapid CYP2C19*17 allele. Kaplan-Meier curves and Cox regression models of 306 patients on tamoxifen treatment for a minimum of 1 year were used to analyze the effect of genotype on relapse-free survival as the primary endpoint.


Through genotype-predicted CYP2C19 (increased↑, normal →, and decreased↓) and CYP2D6 (below↓ and above↑ 50%) phenotypes and combinations thereof, we show here that the group with worst outcome and highest risk of relapse is that of 2C19↑-2D6↓. The 2C19↑ -2D6↓ subgroup was found to be associated with a hazard ratio (HR) of 2.94 [98.75% multiplicity corrected confidence interval (CI); 1.24 - 6.97] when adjusting for age, Nottingham prognostic index and adjuvant chemotherapy, and compared to the remainder of patients. This can be related to the lower adjusted HR of 2.13 (95% CI; 1.23-3.68) when using CYP2D6 genotype alone. Furthermore, the higher risk of relapse for patients with the 2C19↑ -2D6↓ genotype-predicted phenotype is greatly enhanced in premenopausal patients (HR = 21.08, 98.75% multiplicity corrected CI; 2.60 - 171.27).


We hypothesize that poor bioactivation of tamoxifen in patients with low CYP2D6 activity and low levels of circulating female sex hormones through high CYP2C19 metabolism represent a tamoxifen treated breast cancer patient group that has worse clinical outcome. Furthermore, we found that the effect of this genotype-predicted phenotype combination on breast cancer relapse was enhanced in premenopausal women, where larger differences in circulating female sex hormones can be envisioned and thus genotype may have a greater effect.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Karolinska Institutet.


This work was supported by grants to Professor Jonas Bergh´s research group from the Swedish County Council, BRECT at the Karolinska Institute, the Swedish Cancer Society and The Knut and Alice Wallenberg Foundation.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.